Proteogenomics-Guided Risk-Based Screening for Coronary Artery Disease: Implementation across Diverse Populations and Equity Considerations

Obwendo N. J.

Faculty of Medicine Kampala International University Uganda

ABSTRACT

Coronary artery disease (CAD) remains the leading cause of global morbidity and mortality, necessitating more effective and equitable preventive strategies. Proteogenomics-guided risk-based screening integrates genomic variation, circulating protein biomarkers, and clinical and environmental data to enhance risk prediction beyond traditional factors. This approach enables identification of individuals at elevated lifetime risk and supports targeted preventive interventions, potentially improving population health outcomes while optimizing resource allocation. However, implementation across diverse populations raises important methodological, ethical, and health-system challenges, including limited cohort diversity, variability in assay performance, data integration complexities, privacy governance, workforce capacity, and affordability constraints. Ensuring equitable deployment requires inclusive cohort development, standardized and validated assays, transparent computational models, and implementation frameworks grounded in community engagement and social determinants of health. Continuous monitoring of analytical validity, clinical validity, clinical utility, and equity metrics is essential within a learning health-system model. Proteogenomics-guided CAD screening, therefore, holds promise as a transformative precision public health strategy, provided that implementation prioritizes fairness, accessibility, and context-specific policy development to avoid exacerbating existing health disparities.

Keywords: Coronary Artery Disease, Proteogenomics, Risk-Based Screening, Precision Public Health, and Health Equity.

CITE AS: Obwendo N. J. (2026). Proteogenomics-Guided Risk-Based Screening for Coronary Artery Disease: Implementation across Diverse Populations and Equity Considerations. RESEARCH INVENTION JOURNAL OF PUBLIC HEALTH AND PHARMACY 5(1): 88-97. https://doi.org/10.59298/RIJPP/2026/518897